DK1501496T3 - Formuleringer indeholdende amiodaron og sulfalkylethercyklodextrin - Google Patents

Formuleringer indeholdende amiodaron og sulfalkylethercyklodextrin

Info

Publication number
DK1501496T3
DK1501496T3 DK03728598.8T DK03728598T DK1501496T3 DK 1501496 T3 DK1501496 T3 DK 1501496T3 DK 03728598 T DK03728598 T DK 03728598T DK 1501496 T3 DK1501496 T3 DK 1501496T3
Authority
DK
Denmark
Prior art keywords
sulfalkyl
formulations containing
ether cyclodextrin
containing amiodarone
amiodarone
Prior art date
Application number
DK03728598.8T
Other languages
Danish (da)
English (en)
Inventor
Karen T Johnson
Atef A Gayed
Gerold L Mosher
Original Assignee
Cydex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Pharmaceuticals Inc filed Critical Cydex Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1501496T3 publication Critical patent/DK1501496T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK03728598.8T 2002-05-04 2003-04-29 Formuleringer indeholdende amiodaron og sulfalkylethercyklodextrin DK1501496T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/139,620 US6869939B2 (en) 2002-05-04 2002-05-04 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
PCT/US2003/013250 WO2003092590A2 (en) 2002-05-04 2003-04-29 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin

Publications (1)

Publication Number Publication Date
DK1501496T3 true DK1501496T3 (da) 2012-03-19

Family

ID=29399340

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11182697.0T DK2402008T3 (en) 2002-05-04 2003-04-29 Formulations containing amiodarone and sulfoalkyl ether-cyclodextrin
DK03728598.8T DK1501496T3 (da) 2002-05-04 2003-04-29 Formuleringer indeholdende amiodaron og sulfalkylethercyklodextrin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11182697.0T DK2402008T3 (en) 2002-05-04 2003-04-29 Formulations containing amiodarone and sulfoalkyl ether-cyclodextrin

Country Status (16)

Country Link
US (1) US6869939B2 (enExample)
EP (2) EP2402008B1 (enExample)
JP (2) JP4764004B2 (enExample)
KR (1) KR100984197B1 (enExample)
AT (1) ATE535239T1 (enExample)
AU (1) AU2003234285B2 (enExample)
CA (1) CA2483774C (enExample)
CY (1) CY1112527T1 (enExample)
DK (2) DK2402008T3 (enExample)
ES (2) ES2567716T3 (enExample)
HU (1) HUE027551T2 (enExample)
IL (2) IL165022A0 (enExample)
MX (1) MXPA04010925A (enExample)
PT (1) PT1501496E (enExample)
SI (2) SI2402008T1 (enExample)
WO (1) WO2003092590A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1713504T (pt) 2004-01-30 2017-08-29 Zoetis Services Llc Conservantes antimicrobianos para obter uma formulação multidose utilizando beta-ciclodextrinas para formas galénicas líquidas
CN101098678A (zh) 2004-04-23 2008-01-02 锡德克斯公司 含有磺基烷基醚环糊精的dpi制剂
US8092559B2 (en) 2004-05-12 2012-01-10 Luca Technologies, Inc. Generation of hydrogen from hydrocarbon bearing materials
US7426960B2 (en) 2005-05-03 2008-09-23 Luca Technologies, Inc. Biogenic fuel gas generation in geologic hydrocarbon deposits
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US7416879B2 (en) 2006-01-11 2008-08-26 Luca Technologies, Inc. Thermacetogenium phaeum consortium for the production of materials with enhanced hydrogen content
BRPI0709409A2 (pt) 2006-03-28 2011-07-12 Javelin Pharmaceuticals Inc composição farmacêutica e método para tratar um mamìfero necessitando de analgesia
EP2003970A4 (en) 2006-03-28 2012-07-11 Javelin Pharmaceuticals Inc FORMULATIONS OF LOW-DOSEED NON-STEROID INFLAMMATORY INHIBITORS AND BETA-CYCLODEXTRIN
US7977282B2 (en) 2006-04-05 2011-07-12 Luca Technologies, Inc. Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material
US7696132B2 (en) 2006-04-05 2010-04-13 Luca Technologies, Inc. Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
PT2061458E (pt) * 2006-09-15 2015-03-11 Univ Minnesota Composições de topiramato e métodos para a sua utilização
US20090270496A1 (en) * 2007-05-03 2009-10-29 Courchesne William E Antifungal compounds
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US8479813B2 (en) 2009-12-16 2013-07-09 Luca Technologies, Inc. Biogenic fuel gas generation in geologic hydrocarbon deposits
EP2335686A1 (en) 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
NL2004260C2 (en) * 2010-02-18 2011-08-22 Univ Amsterdam Disinfectant composition and its use in dental treatment.
AU2011264919A1 (en) * 2010-06-11 2013-01-10 Baxter Healthcare S.A. Formulations including amiodarone and salts thereof and methods of their manufacture and use
EP2734212B1 (en) 2011-07-20 2017-09-06 Hospira, Inc. Compositions comprising diclofenac for the treatment of post-operative pain
SG11201401597TA (en) 2011-11-29 2014-05-29 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
EP3415153A1 (en) * 2012-01-30 2018-12-19 Baxalta GmbH Non-anticoagulant sulfated or sulfonated polysaccharides
PL3702374T3 (pl) 2012-02-15 2022-11-21 Cydex Pharmaceuticals, Inc. Sposób wytwarzania pochodnych cyklodekstryny
WO2013130666A1 (en) 2012-02-28 2013-09-06 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
US9004162B2 (en) 2012-03-23 2015-04-14 Transworld Technologies Inc. Methods of stimulating acetoclastic methanogenesis in subterranean deposits of carbonaceous material
CA2887057A1 (en) * 2012-10-17 2014-04-24 Sapiotec Gmbh Anthocyanidin complex for the treatment of multiple myeloma
UA121095C2 (uk) 2012-10-22 2020-04-10 Сідекс Фармасьютікалс, Інк. Композиції алкілованого циклодекстрину і способи їх одержання і застосування
CN104870001B (zh) * 2012-11-15 2019-01-18 赛博尔泰克股份公司 用作消炎或免疫抑制有效成分的飞燕草素络合物
EP2773033B1 (en) 2013-02-28 2018-12-05 Dialog Semiconductor GmbH Divide by 2 and 3 charge pump methods
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
EP3183295B1 (en) 2014-08-22 2023-08-02 CyDex Pharmaceuticals, Inc. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
US10736891B2 (en) * 2016-01-07 2020-08-11 Roy MADIGAN Composition and method for treating chagas disease
US11166911B2 (en) * 2016-03-04 2021-11-09 Sun Pharmaceutical Industries Limited Parenteral dosage form of amiodarone
CN107753439A (zh) * 2016-08-22 2018-03-06 黑龙江迪龙制药有限公司 一种注射用盐酸胺碘酮及其制备方法
CA3043979A1 (en) 2016-11-18 2018-05-24 Aicuris Anti-Infective Cures Gmbh Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
US12416024B2 (en) 2018-03-29 2025-09-16 Transworld Technologies Inc. Biologically enhanced oil recovery methods
WO2020232274A1 (en) * 2019-05-15 2020-11-19 Bexson Biomedical, Inc. Ketamine formulation for subcutaneous injection
CA3149914A1 (en) 2019-08-06 2021-02-11 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
JP2023551145A (ja) 2020-11-18 2023-12-07 ベクソン バイオメディカル,インク. 医薬化合物の錯化剤塩製剤
CN115969833A (zh) * 2023-01-03 2023-04-18 上海上药第一生化药业有限公司 胺碘酮药物组合物、注射液及其制备方法及含其的注射器

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004026A1 (en) 1989-09-14 1991-04-04 Australian Commercial Research & Development Limited Drug delivery compositions
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0518930A4 (en) 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
US5234949A (en) 1992-04-01 1993-08-10 Academic Pharmaceuticals, Inc. Parenteral solutions containing amiodarone in acetate buffer solution
FR2735978B1 (fr) * 1995-06-30 1997-09-19 Sanofi Sa Composition pharmaceutique d'amiodarone pour administration parenterale
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
EE200100382A (et) 1999-01-21 2002-12-16 Bristol-Myers Squibb Company Ras-farnesüültransferaasi inhibiitori ja sulfobutüüleeter-7-ß-tsüklodekstriini või 2-hüdroksüpropüül-ß-tsüklodekstriini kompleks ja selle valmistamise meetod
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
GB9921958D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
US6479541B1 (en) * 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration

Also Published As

Publication number Publication date
JP5656692B2 (ja) 2015-01-21
SI1501496T1 (sl) 2012-04-30
PT1501496E (pt) 2012-02-20
AU2003234285A1 (en) 2003-11-17
KR20040106452A (ko) 2004-12-17
EP2402008A1 (en) 2012-01-04
AU2003234285B2 (en) 2007-01-04
EP1501496A4 (en) 2006-05-31
EP1501496A2 (en) 2005-02-02
ES2378306T3 (es) 2012-04-11
DK2402008T3 (en) 2016-05-02
CA2483774C (en) 2011-07-19
IL165022A (en) 2011-08-31
US20030216353A1 (en) 2003-11-20
MXPA04010925A (es) 2005-02-14
EP1501496B1 (en) 2011-11-30
SI2402008T1 (sl) 2016-05-31
HUE027551T2 (en) 2016-10-28
CA2483774A1 (en) 2003-11-13
KR100984197B1 (ko) 2010-09-28
JP2011116776A (ja) 2011-06-16
US6869939B2 (en) 2005-03-22
ATE535239T1 (de) 2011-12-15
IL165022A0 (en) 2005-12-18
JP4764004B2 (ja) 2011-08-31
WO2003092590A3 (en) 2004-01-22
JP2005530744A (ja) 2005-10-13
ES2567716T3 (es) 2016-04-26
EP2402008B1 (en) 2016-01-27
WO2003092590A2 (en) 2003-11-13
CY1112527T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
DK1501496T3 (da) Formuleringer indeholdende amiodaron og sulfalkylethercyklodextrin
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
ATE415817T1 (de) Agrochemische formulierungen
NO20030374L (no) Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
SI1425001T1 (sl) Fenetanolaminski derivati za zdravljenje respiratornih bolezni
CY1107942T1 (el) Ψεκασιμη συνθεση για τη χορηγηση παραγωγων της βιταμινης d
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
DK1423384T3 (da) Pyridinderivater som Raf kinaseinhibitorer
DK1311256T3 (da) Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
ATE299854T1 (de) Chinonverbindungen zur behandlung von krankheiten
ITBO20000453A0 (it) Apparecchiatura e procedimento per la sterilizzazione del terreno .
DE60318327D1 (de) Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe
DE60228988D1 (de) Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
PT1406859E (pt) Derivados substituídos de 4-aminociclo-hexanol
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
NO20060655L (no) 2-alkyliden-19-Nor-vitamin D derivater for behandling av osteofeni eller osteoporose hos hannkjonn
SE0300830D0 (sv) New formulations and use thereof
WO2003040119A8 (fr) Inhibiteurs de l'angiogenese
UA38352A (uk) Засіб для лікувальних ванн
ITMI20031651A1 (it) Apparecchio per la produzione di aerosol ad uso medicale.
DE60209703D1 (de) Verwendung eines alpinia officinarum wurzelstöcke extraktes
ITPD20030113A1 (it) Dispositivo per la lavorazione dei tacchetti delle stecche da biliardo.
IT1321291B1 (it) Apparato per controllare strumentalmente monconi di elementischeletrici nella riduzione delle fratture ossee.
ITRM20030362A1 (it) Tutore per il trattamento delle stenosi esofagee.